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Genome-wide meta-analysis associates HLA-
DQA1/DRB1 and LPA and lifestyle factors with
human longevity
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Genomic analysis of longevity offers the potential to illuminate the biology of human aging.
Here, using genome-wide association meta-analysis of 606,059 parents’ survival, we
discover two regions associated with longevity (HLA-DQA1/DRB1 and LPA). We also validate
previous suggestions that APOE, CHRNA3/5, CDKN2A/B, SH2B3 and FOXO3A inﬂuence
longevity. Next we show that giving up smoking, educational attainment, openness to new
experience and high-density lipoprotein (HDL) cholesterol levels are most positively
genetically correlated with lifespan while susceptibility to coronary artery disease (CAD),
cigarettes smoked per day, lung cancer, insulin resistance and body fat are most negatively
correlated. We suggest that the effect of education on lifespan is principally mediated
through smoking while the effect of obesity appears to act via CAD. Using instrumental
variables, we suggest that an increase of one body mass index unit reduces lifespan by
7 months while 1 year of education adds 11 months to expected lifespan.
DOI: 10.1038/s41467-017-00934-5 OPEN
Correspondence and requests for materials should be addressed to P.K.J. (email: peter.joshi@ed.ac.uk)
#A full list of authors and their afﬂiations appears at the end of the paper
NATURE COMMUNICATIONS |8:  910 |DOI: 10.1038/s41467-017-00934-5 |www.nature.com/naturecommunications 1
Longevity is of interest to us all, and philosophers have longspeculated on the extent to which it is pre-determined byfate. Here we focus on a narrower question—the extent and
nature of its genetic basis and how this inter-relates with that of
health and disease traits. In what follows, we shall use longevity as
an umbrella term. We shall also more speciﬁcally refer to lifespan
(the duration of life) and long-livedness (living to extreme old
age, usually deﬁned by a threshold, such as 90 years). Up to 25%
of the variability in human lifespan has been estimated to be
genetic1, but genetic variation at only three loci (near APOE,
FOXO3A and CHRNA3/5)2–5 have so far been demonstrated to
be robustly associated with lifespan.
Prospective genomic studies of lifespan have been hampered
by the fact that subject participation is often only recent,
allowing insufﬁcient follow-up time for a well-powered analysis of
participant survival. On the other hand, case-control studies of
long-livedness have had success2, 3, 6 and some technical appeal
(focussing on the truly remarkable), but such studies can be
limited and costly in their recruitment. We recently showed that
the extension of the kin-cohort method7 to parental lifespans,
beyond age 40, of genotyped subjects could be used to
detect genetic associations with lifespan with some power in
genomically British participants in UK Biobank (UKB)4. Here we
extend that approach in a genome-wide association meta-analysis
(GWAMA) to discovery across UKB European- and
African-ancestry populations and 24 further population studies
(LifeGen), mainly from Europe, Australia and North America, to
search for further genetic variants inﬂuencing longevity. We
then use those GWAMA results to measure genetic correlations
and carry out Mendelian randomisation (MR) between other
traits and lifespan seeking to elucidate the underlying effects
of disease and socio-economic traits on longevity, in a framework
less hampered by confounding and reverse causality than
observational epidemiology.
Results
Genome-wide association study. In total, 606,059 parental
lifespans were available for analysis, of which 334,974 were
already complete (Table 1).
In our GWAS of 586,626 European parental lifespans, we ﬁnd
four regions HLA-DQA1/DRB1, LPA, CHRNA3/5 and APOE, in
which the lead SNPs rs34831921, rs55730499, rs8042849 and
rs429358, respectively, associate with survival at genome-wide
signiﬁcance (p< 5 × 10−8) (Table 2, Fig. 1a, b, Fig. 2a–d). The
two previously unreported loci, rs34831921 (HLA-DQA1/DRB1)
and rs55730499 (LPA), both showed statistically signiﬁcant,
directionally consistent, evidence of association at the proxy SNPs
in strongest LD in the largest (5406 cases, 15,112 controls)
publicly available set of GWAS summary statistics for extreme
long-livedness (CHARGE-EU 90+)6, with p< 0.0035 for both
SNPs. As our GWAS results were of the observed effect of
offspring genotype on parent phenotype and the actual effect of
carrying an allele for the individual concerned (rather than their
parent) is twice that observed in a parent-offspring kin-cohort
study4, all reported effect sizes (and their standard errors)
throughout this manuscript have been doubled to give the
estimated effect size in the allele carriers themselves. The hazard
ratios for one copy of the minor alleles were 0.942 and 1.074
for rs34831921 (HLA-DQA1/DRB1) and rs5573049 (LPA),
respectively, corresponding to an increase/decrease in lifespan
of ~ 0.6/0.7 years for a carrier of one additional copy of the
minor allele.
We meta-analysed our results with the CHARGE-EU 90+
longevity GWAMA6 summary statistics using Z-scores and equal
weights for each study, reﬂecting their similar statistical power.
We found strengthened signals, substantially at APOE
(rs4420638, p= 5.4 × 10−41) and slightly in the LPA region
(rs1045587, p= 2.05 × 10−11). No improvement of statistical
signiﬁcance was observed in the HLA-DQA1/DRB1 region,
where there were no SNPs in strong LD with the lead LifeGen
SNP, nor was there an increase in signiﬁcance near CHRNA3/5.
However, in this meta-analysis one further region near AKAP7/
EPB41L2 on chromosome 6 just reached genome-wide signiﬁ-
cance (rs1919453, A allele frequency= 0.36, p= 4.34 × 10−8;
Fig. 1c, Supplementary Fig. 1), and the observed hazard ratio
(SE) for the minor allele was 0.976 (0.0056) in LifeGen alone.
In our study of 9359 father and 10,074 mother lifespans in
participants with African ancestry, no SNPs were genome-wide
(GW) signiﬁcant in the analysis of both parents combined.
However, we found one GW signiﬁcant signal (rs10198124,
G allele frequency 0.39 in African subjects), in an intergenic
region of chromosome 2 associating with lifespan for fathers
(HR (SE) for G allele= 1.22 (0.0354), p= 1.66 × 10−8), with
a consistent direction of association in all 9 cohorts studied. No
association was observed at this SNP in African mothers, or
fathers and mothers of European ancestry (HR (SE)= 0.97
(0.038), 1.01 (0.007) and 1.00 (0.008), p= 0.51, 0.21 and 0.77,
respectively (Fig. 1d, Supplementary Fig. 2A−D).
Cross-validation of candidate genes. We next attempted
to validate 13 candidate genes identiﬁed in previous longevity
studies. In our study, only three of these genes showed statistically
signiﬁcant, directionally consistent evidence (p< 0.0003,
two-sided test) of association; CDKN2A/B, SH2B3 and FOXO3A
(Fig. 3, Supplementary Fig. 3 and Supplementary Data 3).
For SH2B3 and FOXO3A our estimated effect sizes are
concordant with those reported from the most robust (i.e.,
narrowest 95% conﬁdence interval (CI)) previous study.
However, for CDKN2A/B, the 95% CI for our estimate is entirely
below that from the more robust of the two studies considered.
Table 1 Summary of the LifeGen parental lifespans
Ancestry Parent Count Mean age
Alive Dead Total Alive Dead All
African Father 2435 6924 9359 72.4 70.4 70.9
African Mother 4185 5889 10,074 73.1 70.7 71.7
European Father 113,611 178,017 291,628 62.9 71.2 68
European Mother 150,854 144,144 294,998 66.2 75.1 70.5
ALL 271,085 334,974 606,059
Summary statistics for the 606,059 parental lifespans that passed phenotypic QC (in particular, parent age> 40) and were analysed here. In practice, fewer lives than these were analysed for some
SNPs, as a SNP may not have passed QC in all cohorts (in particular within cohort MAF> 1%). The mean age of alive parents across European cohorts was reduced by the large iPSYCH cohort, of
relatively younger subjects and thus parents, who were predominantly alive (mean father/mother age among the alive parents in iPSYCH was 52.4/50.4)
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No statistically signiﬁcant (p> 0.22, two-sided test) evidence of
association was found for the other 10 genes. In all cases (with the
possible exceptions of ABO and 5q33) our estimates of the odds
ratio were close to 1 and our 95% CI did not include previous
estimates, suggesting, at least for the remaining 8 SNPs (at or near
CAMK4, C3orf21, GRIK2, IL6, RGS7, CADM2, MINPP1 and
ANKRD20A9P), that our non-replication did not arise solely from
lack of power.
Consistent with our previous reports4, we found age-speciﬁc
and sex-speciﬁc effects of the lead SNPs in the APOE and
CHRNA3/5 loci. For APOE, the hazard ratio (SE) of the lead SNP
was 1.07 (.01) for men and 1.13 (.01) for women, whereas for
CHRNA3/5 it was 1.07 (.01) for men and 1.04 (.01) for women
(Fig. 4a). Conversely, for APOE, hazard ratios stratiﬁed by age
were 1.06 (.01) for ages 40−75 and 1.14 (.01) for ages 75+,
whereas for CHRNA3/5 they were 1.08 (.01) for 40−75 and 1.03
(.01) for age 75+ (Fig. 4b), with similar patterns when stratifying
by age and sex at the same time, (Fig. 4c), although the distinc-
tions between men and women for CHRNA3/5 disappeared
beyond age 75. For LPA, CDKN2B and SH2B3, there was no
statistically signiﬁcant evidence of age-speciﬁc or sex-speciﬁc
effects, while the HLA and FOXO3 variants showed age but not
sex-speciﬁc effects (Fig. 4a, b), with the HLA locus having a
greater effect at younger ages (40−75) while, conversely, the
FOXO3 locus had greater effect at older ages(75+).
We tested the four SNPs identiﬁed in the discovery phase
(Table 2) for association with other ageing traits, using
PhenoScanner8, an on-line tool which searches 88 complex trait
GWAMAs and three GWAS catalogues. For the SNP in the LPA
region, associations were found with blood lipids and coronary
traits. For the SNP in the HLA region, we found associations with
rheumatoid arthritis and Crohn’s disease. For the CHRNA3/5
region, we found associations with traits which associate with
smoking behaviour: nicotine dependence, lung cancer, chronic
obstructive pulmonary disease and schizophrenia. Finally, for
the APOE region, we saw associations with Alzheimer’s disease,
age-related macular degeneration, blood lipids, adiposity, cardiac
and cognitive ageing traits (Supplementary Data 4).
Genetic correlation of complex traits with lifespan. We
estimated the genetic correlation between 113 complex quanti-
tative and disease susceptibility traits and lifespan using LD Score
regression9: 46 showed meaningful genetic correlations (rg) with
lifespan (statistically signiﬁcant, |rg| > 0.15). The most strongly
correlated with mortality were coronary artery disease (CAD)
and cigarettes smoked per day, rg (SE)= 0.66 (0.05) and 0.58
(0.11), respectively. Those most negatively correlated were years
of schooling and former vs. current smoker, rg (SE)= −0.47
(0.05) and −0.64 (0.09), respectively (Supplementary Fig. 4,
Supplementary Data 5). Lung cancer, type 2 diabetes and insulin
resistance also correlated relatively strongly with earlier mortality,
while increased age at ﬁrst birth, openness to experience
(a personality trait reﬂecting curiosity vs. caution, determined by
questionnaire) and high-density lipoproteins (HDL) cholesterol
were correlated with later death.
Estimates for rg between 9 traits and mortality and their 95%
CI fell wholly within the range [−0.15, 0.15], which we have
labelled not meaningfully correlated with lifespan. These were
femoral neck and lumbar spine bone mineral density,
serum creatinine, extreme height, height, bipolar disorder,
schizophrenia, autism spectrum disorder and platelet count.
For the remaining 55 traits, there was insufﬁcient statistical
power to distinguish whether the rg fell within or outside [−0.15,
0.15].
Given the similarity in deﬁnition of many traits (e.g., obesity
classes) and the strong correlations between others, we clustered
the 46 traits which showed a signiﬁcant and meaningful rg into
nine clusters. Positive genetic correlations with mortality for
the clusters ranged from 0.68 (smoking) to 0.17 (rheumatoid
arthritis and breast cancer), whilst negative correlations varied
from −0.50 (education) to −0.15 (age at menarche); (Fig. 5,
Supplementary Data 5). We found that the beneﬁcial trait
clusters for education and happiness group together, as do a core
group of factors (obesity, dyslipidemia/waist-hip ratio (DL/
WHR), type 2 diabetes, CAD and smoking) which show stronger
correlation not only to mortality but also among each other, while
albuminuria and blood pressure seem to form their own risk
cluster. We next considered whether and to what extent the
observed correlations between mortality and the trait clusters are
mediated through other clusters, using partial correlations. In
most cases, there was relatively little difference between
correlations and partial correlations with mortality (Supplemen-
tary Table 1) and the direction of effects remained the same. On
the whole, the correlation of each risk cluster is therefore not
mainly mediated via other clusters. However, the entire
correlation of the DL/WHR cluster with lifespan was 0.41,
whereas its partial correlation was −0.18, implying that one or
more of the other clusters inﬂuenced the genetic correlation,
likely CAD with which it is strongly correlated and whose partial
correlation did not fall in the same manner. Similarly, the
entire correlation of the education cluster with lifespan
fell from −0.50 to −0.18 as a partial correlation, in this case
apparently due to mediation through smoking behaviour. Blood
pressure and age at menarche also showed reductions in partial
rg, to near zero for age at menarche, consistent with mediation by
other traits.
Causal relationships with lifespan. Finally, we used MRbase10
and further summary statistics for breast cancer (BCAC11) and
C-reactive protein (CHARGE-CRP12) made available to us to
Table 2 Four regions associated with lifespan at genome-wide signiﬁcance and replication via proxy SNPs in CHARGE
rsid Gene a1 Freq a1 N(000) parent HR a1 SE P-value Years Proxy r2 CHARGE P Dir.
rs34831921 HLA-DQA1 /DRB1 A 0.09 481 0.942 0.011 4.18 E-08 0.6 rs3129720 0.39 0.003 +
rs55730499 LPA T 0.083 563 1.074 0.011 8.67 E-11 −0.7 rs10455872 0.97 0.002 −
rs8042849 CHRNA3/5 C 0.356 567 1.046 0.006 3.75 E-14 −0.4 rs9788721 0.98 0.951 −
rs429358 APOE C 0.142 556 1.091 0.008 1.44 E-27 −0.9 rs6857 0.69 2E-20 −
a1 the effect allele, CHARGE, CHARGE European GWAS for survivorship beyond age 90 vs. younger controls,6 CHARGE P, the p-value for the two-sided test of association between proxy and long-
livedness in CHARGE, Dir. direction of effect of a1 in CHARGE: “ + ” means long-livedness increasing, “−“ means long-livedness decreasing, Freq. frequency, N(000) count (thousands of parents with
lifespan and subject genotype information), HR, Hazard Ratio, P p-value for the Wald test of association between imputed dosage for a1 and lifespan, Proxy, the closest proxy SNP in CHARGE, r2 the
linkage disequilibrium between the discovery SNP and its CHARGE proxy, in the 1000 genomes EU panel, SE, Standard Error, Years the number of additional years of lifespan expected for a carrier of one
additional copy of a1. There are four overlapping cohorts between the two studies; EGCUT, NTR, PROSPER and RS1, but only RS1 contributed cases to the CHARGE: out of all 5406 cases analysed in
CHARGE, 892 cases (from RS1) overlapped the 300,000 genotyped subjects studied in discovery and the phenotyped individuals were in any case not the same
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perform two-sample Mendelian randomisation to investigate
causal inﬂuences on lifespan. Of more than 90 tested phenotypes,
seven risk factors (cigarettes smoked per day, HDL cholesterol,
LDL cholesterol, fasting insulin, systolic blood pressure and CRP)
and six disease susceptibilities (Alzheimer’s disease, breast cancer,
CAD, ischaemic stroke, squamous cell lung cancer and type 2
diabetes) signiﬁcantly associated with mortality (Table 3).
Smoking causally reduced lifespan by 6.8 years for lifelong
smoking of one pack of 20 cigarettes a day, BMI reduced life
by 7 months per unit, while education causally increased lifespan
by 11 months for each further year spent studying. In contrast to
the genetic correlations (rg CRP: mortality= 0.35), genetically
raised CRP seems to have a life-lengthening effect: 5.5 months of
increased lifespan per log mg/L.
We compared the relative strengths of these different
phenotypic effects on lifespan using a measure independent of
scale: extrapolating the genetic effects across the interquartile
phenotypic range. Variation in smoking and systolic blood
pressure had the strongest causal life-shortening effects (5.3 and
5.2 years, respectively), followed by fasting insulin, body mass
index and CAD, while years of education showed by far the most
beneﬁcial effect (4.7 years), when comparing the estimated effect
of moving from the ﬁrst to the third quartile of the phenotype
distribution. Similarly, we estimate moving from the bottom to
the top of the interquartile phenotypic range of CRP increases
lifespan by 0.7 years.
Discussion
We replicated previous ﬁndings of genome-wide signiﬁcant
associations between longevity and variants at CHRNA3/5 and
APOE and discovered two further associations, at LPA and HLA-
DQA1/DRB1, with replication of the further associations in a
long-livedness study. We found no evidence of our lead SNPs at
the CHRNA3/5, LPA and HLA-DQA1/DRB1 loci associating with
traits other than smoking behaviour, cardio-metabolism and
rheumatoid arthritis, respectively, while ﬁnding more pleiotropy
at APOE. We also robustly replicated previous work suggesting
associations with longevity at CDKN2A/B, SH2B3/ATXN2 and
FOXO3A. We found no evidence of association between lifespan
and the other 10 loci previously found to suggestively associate
with lifespan, despite apparent power to do so. We showed strong
negative genetic correlation between CAD, smoking and type 2
diabetes and lifespan, while education and openness to experience
were positively genetically correlated. Using MR, we found that
moving from the 25th to 75th percentile of cigarettes per day,
systolic blood pressure, fasting insulin and BMI causally reduced
lifespan by 5.3, 5.2, 4.1 and 3.8 years, respectively, and similarly
moving from the 25th to 75th percentile of educational attainment
causally extended lifespan by 4.7 years. Strikingly, we also found
that increased CRP increases lifespan, as a causal effect, the
reverse of its correlation.
Lipoprotein(a) is a spherical lipoprotein carrying cholesterol
and triglycerides in the bloodstream13. Variation in LPA has
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been extensively studied14, and found to inﬂuence cardiovascular
disease15 and type 2 diabetes16. A close proxy to our lead SNP
(rs10455872, r2= 0.97) has been strongly associated with
decreased Lp(a) size and increased Lp(a) plasma concentration
and is one of the strongest predictors of coronary heart
disease risk with an odds ratio of 1.7 per allele, consistent across
populations17, all suggesting that rs55730499 affects mortality by
increasing Lp(a) levels and susceptibility to cardiovascular events.
The large major histocompatibility complex (MHC)
encompasses HLA-DQA1/DRB1. MHC class II genes encode
components of the antigen-presenting apparatus and are the most
polymorphic region of the human genome. Genes within the
MHC have previously been associated with many autoimmune
conditions and other traits, including psoriasis18, rheumatoid
arthritis19, multiple sclerosis20 and T1D21. In a recent informed
GWAS of longevity, Fortney et al.22 identiﬁed, but failed to
replicate, two variants close to the HLA-DRA locus22.
The FOXO3A locus has been repeatedly reported by other
studies3, 23 as associating with extreme longevity. Variant
rs3800231, which exhibits the strongest association in our data,
seems to exert its beneﬁcial effect on people aged above 75
but may have a neutral, or deleterious effect at younger ages,
supporting the consensus that FOXO3A plays a putative role in
extreme longevity and general health into old age. This contrasts
our ﬁndings for the CHRNA3/5, LPA, HLA-DQA1/DRB1 loci,
where effects appear to be speciﬁc to disease susceptibility,
rather than general ageing. The CDKN2A/B locus at 9p21 has
previously been associated with CAD24, while the missense allele
rs3184504-T we identiﬁed within the SH2B3/ATXN2 locus
has been previously associated with increased risk for type 1
diabetes25, diastolic blood pressure26 and several autoimmune
conditions27–29.
The failure to replicate previous ﬁndings for lifespan increases
at ABO and 5q33.3/EBF1 may be due to a combination of limited
power in our study, despite its size, and a degree of winner’s curse
in previous ﬁndings. However, for CAMK4, C3orf21, GRIK2, IL6,
RGS7, CADM2, MINPP1 and ANKRD20A9P, our ﬁndings appear
inconsistent with the previous work, suggesting those ﬁndings
were either false positive associations, or differences in effects are
due to the differences between the types of lives studied by us and
other studies.
The use of different cohorts from a diverse range of countries
with common shared ancestry is common in GWAMA and
potentially gives rise to heterogeneity in effect sizes, whatever the
trait under consideration. However, a study of lifespan is perhaps
particularly susceptible to such effects, as mean lifespans vary by
cohort (Supplementary Data 2) and genetic effects might vary by
environment. Nonetheless, such heterogeneity is not relevant
under the null hypothesis (effect size= 0 in all cohorts) and
so will not have induced false positives. On the other hand,
10
a b
c d
100
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)
80
60
40
20
0
100
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)80
60
40
20
0
100
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)
80
60
40
20
0
100
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)
80
60
40
20
0
15
10
5
0
8 rs34831921
rs55730499
rs429358
rs8042849
0.8
0.6
0.4
0.2
r 2
0.8
0.6
0.4
0.2
r 2
0.8
0.6
0.4
0.2
r 2
0.8
0.6
0.4
0.2
r 2
6
4
–
lo
g 1
0(p
-
va
lu
e)
–
lo
g 1
0(p
-
va
lu
e)
2
0
10
8
6
4
–
lo
g 1
0(p
-
va
lu
e)
–
lo
g 1
0(p
-
va
lu
e)
2
0
30
25
20
15
10
5
0
HCG23
DNAJA4
WDR61
CRABP1
IREB2
HYKK
PSMA4
CHRNA5
CHRNA3
CHRNB4
LOC646938
ADAMTS7
HLA–DRB5
HLA–DRB6
HLA–DRB1
HLA–DQA1
HLA–DQB1
HLA–DQA2
HLA–DQB2
HLA–DOB
TAP2
PSMB8
PSMB8–AS1
TAP1
PSMB9 SLC22A3
PVR
CEACAM19
CEACAM16
BCL3
MIR8085
CBLC
BCAM PVRL2 APOC1
TOMM40
APOE
APOC1P1
CLPTM1
RELB
CLASRP
ZNF296
GEMIN7
NKPD1
PPP1R37
APOC4
APOC4–APOC2
APOC2
LPAL2 LPA PLG
BTNL2
HLA–DRA
32.4 32.5 32.6
Position on chr6 (Mb)
32.7 32.8 160.8 160.9 161
Position on chr6 (Mb)
161.1 161.2
45.2 45.3 45.4
Position on chr19 (Mb)
45.5 45.678.6 78.7 78.8
Position on chr15 (Mb)
78.9 79
Fig. 2 Locus zoom plots for four genome-wide signiﬁcant associations with lifespan. Results from the meta-analysis of subjects of European ancestry
analysis, for both parents combined. The displayed p-value corresponds to that of a two-sided test of association between the SNP and parent lifespan
under the Cox model. a The rs34831921 variant, at the HLA-DQA1/DRB1 locus, P= 4.18E-08. b The rs55730499 variant, at the LPA locus, P= 8.67E-11.
c The rs8042849 variant, at the CHRNA3/5 locus, P= 3.75E-14. d The rs429358 variant, at the APOE locus, P= 1.44E-27
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00934-5 ARTICLE
NATURE COMMUNICATIONS |8:  910 |DOI: 10.1038/s41467-017-00934-5 |www.nature.com/naturecommunications 5
heterogeneity may have reduced power and estimated effect sizes
should perhaps be considered as (sample-weighted) averages over
the cohorts participating.
The lack of observed genetic correlation between mortality and
schizophrenia is perhaps surprising, given the known increased
risk of early death due to schizophrenia30, however, here we study
lifespan after the age of 40, where the effect of schizophrenia
relative to other causes of mortality is less pronounced. We
conjecture that a study of early mortality might show a different
pattern, but believe the parent-offspring kin-cohort method
would be less suitable, as parents would have to survive beyond
reproduction to be available for study. The albuminuria cluster,
which correlated with mortality, is understood to be a
consequence of poor glomerular ﬁltration arising from chronic
kidney disease, often attributable to diabetes or high blood
pressure31. Our ﬁnding that the happiness cluster (depressive
symptoms and subjective well-being) has a beneﬁcial correlation
with lifespan (rg= 0.24), is in line with a recent meta-analysis
which has shown a life-lengthening effect of subjective well-being
on lifespan32. Similarly, depression has been shown to increase
mortality, and is one of the strongest quality-adjusted life
expectancy losses, twice as much as better-studied risk factors
such as smoking, heart disease, stroke and diabetes33. Our results
thus reinforce the importance of public policy focusing not only
on physical health but also on general well-being in order to
increase life expectancy and quality34.
In general the results of the MR analyses appear consistent with
those of the LD score regression estimates. This might be
expected since the main difference is that MR compares two
phenotypes using just a small number of SNPs which the
underlying GWAS were powered to ﬁnd, and LD score regression
uses the whole genome. Nevertheless, as a result the latter may
indicate a shared heritable confounding factor, rather than a
causal effect, which appears to be the case for our CRP results, as
the measured effect of CRP on lifespan is in the opposite direction
to the genetic correlation. CRP’s effects per se are not well
understood, but our results lead us to speculate it may have a
protective function, rising in the presence of disease, rather than
causing it, despite observational associations with disease and
consequent attempts to develop a drug to reduce it35. If true, this
pattern is somewhat analogous to ﬁndings for the N-terminal
fragment of pro-BNP, which is a protective molecule, but
observationally positively associates with cardiac failure and
adverse cardiovascular outcomes36. Our ﬁnding that a reduction
in one BMI unit leads to a 7-month extension of life expectancy,
appears broadly consistent with those recently published by the
Global BMI Mortality Collaboration, where great effort was made
to exclude confounding and reverse causality37. We also found
each year longer spent in education translates into approximately
a year longer lifespan. When compared using the interquartile
distance, risk factors generally exhibited stronger effects on
mortality than disease susceptibility. Although both CAD and
cigarette smoking show a very similar genetic correlation with
lifespan, the measured effect of smoking is twice as large as that of
CAD, perhaps because smoking inﬂuences mortality through
multiple pathways.
Our results show that longevity is partly determined by the
predisposition to common diseases and, to an even greater extent,
by modiﬁable risk factors. The genetic architecture of lifespan
appears complex and diverse and there appears to be no single
genetic elixir of long life.
Methods
Genome-wide association. As is conventional in GWAMA, analysis was carried
out locally at each cohort and then meta-analysed centrally. Initial phenotype and
genotype quality control were carried out in accordance with local standards, with
variants imputed to 1000 Genomes (typically phase 1, version 3). Cohort char-
acteristics, including genotyping and imputation methods and summary statistics
of the parental lives analysed are described in Supplementary Datas 1 and 2. Study
protocols were approved by the relevant committees for each of the local cohorts.
Written informed consent was obtained from each participant in each study.
We conducted an association test between parental survival (age and alive/dead
status) and offspring genotype. To do so, survival traits were transformed into
residuals, permitting analysis as quantitative traits. To facilitate standardisation
across the GWAS consortium, residuals for GWAS were calculated in accordance
with the analysis plan set out below using a common R protocol distributed to all
groups. These residual traits were then tested for association in a GWAS over the
imputed SNP panel.
Parents who died below the age of 40 were excluded. Analysis was thus of
survivorship beyond the age of 40. Association testing was conducted under the
following Cox Proportional Hazards Model38,
h xð Þ ¼ h0 xð ÞeβXþγ1Z1þ¼þγkZk
h0 is the baseline, β the hazard loge ratio associated with X (the effect allele count)
and Z1,…., Zk the other variables ﬁtted i.e., subject sex, and the ﬁrst 10 PCs of
genetic structure along with each studies’ usual further covariates, such as batch or
assessment centre.
Rather than ﬁt the full model in one step, we calculated Martingale residuals of
the Cox model (excluding X). Martingale residuals39 are,
bMi ¼ δi  bΛ0 τið Þebγ1Z1þ¼þbγkZk
where δi and τi are the parent status (1—dead/, 0—alive at assessment date) and age
of the ith individual, bγ1¼ bγk are effect estimates of, Z1,…., Zk. Where the allele
count, X, has an effect, bMi has a linear association with it39.
However, although these residuals are associated proportionately with the
hazard ratio and thus permit statistical hypothesis testing, their relationship with
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Fig. 3 Validation of associations reported elsewhere by lookup in LifeGen.
A search of recent literature suggested the gene regions shown here were
most likely to harbour associations with lifespan, beyond the four loci
identiﬁed in Table 2, which are further explored in the Discussion. The most
powerful LifeGen analysis (i.e., European ancestry, father and mother
combined) was used for validation. The odds ratio (OR) for extreme long-
livedness is presented for the reported life-shortening allele (i.e., the OR for
long-livedness< 1) in the original study, but not necessarily in LifeGen. The
LifeGen OR of being long-lived was estimated empirically on the
assumption that the relationship between the LifeGen observed hazard
ratio (HR) and the OR is stable across allelic effects, with APOE results
from LifeGen and CHARGE-EU 90+ 6 being used to estimate the ratio of ln
HR to ln OR (−4.7). These estimates will only fully align with the published
ORs if the shape of the effect on lifespan is similar to APOE, as is true under
the proportional hazards assumption, nonetheless the pattern is suggestive.
Further details are shown in Supplementary Data 3
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the hazard ratio depends of the (parent) population structure, in particular the
proportion dead. The Martingale residuals were therefore scaled up by 1/
(proportion dead) separately for each parent gender, to give a residual trait with a
1:1 correspondence with the hazard ratio39. This transformed trait was then tested
for association with each SNP separately under the following (additive) model,
P ¼ βX þ e
where β is the effect size of the SNP (and an estimate of the HR) and X the non-
reference allele count of the marker, with e being normally distributed and
independent. Despite this efﬁcient approach, runtimes in UK Biobank were still
potentially onerous, so RegScan 0.240 was used there as it is ideally suited for
multiple, residualised traits in large data sets.
For cohorts with signiﬁcant relatedness, all but one subject amongst relatives
with coefﬁcient of kinship > 5% were excluded, to create a (smaller) unrelated
population, in preference to conventional (potentially more powerful) mixed
modelling among family based studies. This was done because the genomic
relationship matrix among offspring does not precisely reﬂect the genetic
covariance among parental traits. As an example, consider the offspring of two
brothers: the correlation between genetic values of the father trait is 0.5, but of the
mother trait is 0, while the Genetic Relationship Matrix (GRM) entry would be 0.25
in both cases. The GRM thus does not fully express covariance among (parent) trait
values across subjects, so the smaller unrelated population was used. Exceptions to
this were for CILENTO, ERF, GeneSTAR, MICROS and OGP, where it was
impractical to exclude relatives, and mixed modelling was used.
After preparing GWAS results locally, cohorts submitted these to the central
team for meta-analysis. The central meta-analysis was carried out in METAL, with
QC following that of Easy-QC41, but sometimes more conservative, as follows. UK
Biobank data were read into METAL42 ﬁrst, standardising all subsequent input
alleles to that imputation. SNPs with mismatching alleles in other GWAS were
rejected. SNPs were removed from a cohort’s GWAS if the minor allele frequency
for that cohort was< 0.01. As all studies had in excess of 500 lives, this meant that
minor allele count exceeded 10 Alleles with an info score (observed variance in
dosage/expected under HWE) < 0.3 were excluded. Each GWAS was checked for
systematic errors in allele coding/frequencies and test statistics for SNPs passing
QC. After QC, SNP counts were 13,689,868 for European fathers, 13,643,373 for
European mothers, 20,305,364, for African fathers and 20,296,065 for African
mothers.
African and European ancestries were meta-analysed separately, as were the
results for each parental sex, using inverse variance meta-analysis in METAL.
Double genomic control was applied. The median λ for 78 GWAS was 0.998 and
the maximum was 1.048, suggesting good control for stratiﬁcation. The highest λ
was for UK Biobank—genomically British, the most powered study. After the ﬁrst
level of genomic control, results were meta-analysed by inverse variance, while
keeping continental ancestry separate and parental sex separate. The λ applied was
1.034, 1.023, 1.027, 1.028, for European fathers, mothers, African fathers, mothers,
respectively. Finally, within continent across parent inverse variance meta-analysis
was applied. As expected, due to environmental correlation among spouses, there
was some inﬂation: λ of 1.107 and 1.094, for Europeans and Africans, respectively,
giving two ﬁnal combined meta-analyses (African and European) for both parents
combined, subject to double genomic control.
These GWAS results were of the observed effect of offspring genotype on parent
phenotype. The actual effect of carrying an allele for the individual concerned
(rather than their parent) is twice that observed in a parent-offspring kin-cohort
study4. All reported effect sizes throughout this manuscript were therefore doubled
to give the estimated effect size in the allele carriers themselves. The effect of hazard
ratios on lifespan was calculated from survival curves of the Cox model by each
cohort. The weighted average effect of hazard ratio on lifespan across all cohorts
and both sexes was that a 1% reduction in hazard extended expected lifespan by
0.108 years. To avoid an undue sense of precision, and in accordance with an
actuarial rule of thumb, where applicable, hazard ratios were converted to
estimated effects on lifespan using a 10% HR: −1 year of lifespan ratio.
Genome-wide signiﬁcant European lead SNPs at each QTL were then looked up
in the largest independent GWAS of lifespan with published summary statistics, for
survivorship beyond age 90 vs. younger controls (CHARGE-EU 90+)6. None of the
lead SNPs were present in that dataset, so proxy SNPs in strongest LD were chosen
using LDlink43, with European populations selected. The SNP showing the highest
r2 with each LifeGen lead SNP was extracted from the CHARGE GWAS. The
Rotterdam study was part of both GWAMAs, but the trait measured was in
different people. In our study, we considered the lifespan of parents, whereas the
long-livedness analysis was in the offspring. The LifeGen and CHARGE-EU 90+
GWAMAs were then meta-analysed using p-values and direction of effect (after
reversing the sign of effect for CHARGE to convert longevity to mortality) with
equal weights placed on each GWAMA, using METAL. The choice of equal
weights was made, rather than weights reﬂecting sample size, because (i) the
CHARGE extreme case-control approach is more powerful per sample than parent
lifespan Cox modelling, and comparison of n is not straightforward, (ii) the Z-test
statistics for rs4420638 (the most signiﬁcant SNP overlapping in both studies) were
similar: 9.4 and 9.5 for CHARGE and LifeGen, respectively, for the same n,
indicating similar overall power.
We used PhenoScanner8 to search for other trait associations with our lead
SNPs. Pheno Scanner settings were: rsid, Catalogue =GWAS, p-value cutoff= .001,
proxies = 1000 G, r2= 0.6.
A review of recent literature was conducted for SNPs that have been associated
with longevity and lifespan by other researchers, to see if we could validate their
results. Nine papers published since 2008 were selected: Broer et al.3, Deelen et al.6,
Emanuele et al.44, Flachsbart et al.45, Fortney et al.22, Malovini et al.46, Newman
et al.47, Willcox et al.23 and Zeng et al.48. Variants with MAF above 1% in 1000
Genomes, from these papers were taken forward, if they exhibited genome-wide
signiﬁcance (p < 5 × 10−8) or they had suggestive associations that were replicated.
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Fig. 4 Age-speciﬁc and sex-speciﬁc effects of the 4 GWS associations in LifeGen and the validated candidate loci. The four GWS and three suggestive
replicated loci were analysed for age-speciﬁc and sex-speciﬁc effects on lifespan. a The variants at APOE and CHRNA3/5 exhibit sexually dimorphic effects
on parental mortality, while all other variants exhibit more modest often non-signiﬁcant sex-speciﬁc differences. b The effects of each gene on male and
female lifespan were meta-analysed and studied in the cases that died aged between 40 and 75 or after 75. APOE exerts a much greater effect in the older
age group, while most of the other genes exhibit the opposite effect. FOXO3 appears neutral, if not positive, in the earlier age group. c Effects on mortality
were studied in both age groups for both sexes. APOE has the strongest effect on females aged 75+, CHRNA3/5 acts on males aged 40−75 and all other
genes display more ambiguous trends
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Fig. 5 Genetic correlations between trait clusters that associate with mortality. The upper panel shows whole genetic correlations, the lower panel, partial
correlations. T2D, type 2 diabetes; BP, blood pressure; BC, breast cancer; CAD, coronary artery disease; Edu, educational attainment; RA, rheumatoid
arthritis; AM, age at menarche; DL/WHR Dyslipidaemia/Waist-Hip ratio; BP, blood pressure
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In aggregate, 18 variants in 13 gene regions were identiﬁed, of which four were
genome-wide signiﬁcant in the original study, while nine were suggestive (Fig. 3).
These lead SNPs were then looked up in our results and compared with the
previously reported associations (Supplementary Data 3 and Fig. 3).
Whilst comparable p-values were directly apparent, we also wished to compare
effect sizes, inter alia to understand whether non-replication in terms of p-value
arose from lack of power or inconsistency in observed effect. However, this was not
straightforward due to the different study designs, principally that we observed
hazard ratios for mortality, while other studies observed odds ratios for extreme
long-livedness (often for slightly different deﬁnitions of cases and controls). We
therefore proceeded as follows. The most signiﬁcant longevity association, APOE,
was used to estimate the relationship between OR observed in case-control studies
and HR observed by us, as follows. For APOE variant rs4420638(G) loge OR for
survival beyond age 90 has been estimated elsewhere as −0.336 and our observed
HR was 0.07, giving an empirical factor of −4.7 to estimate ORs for case-control
extreme long-livedness from lifespan HRs. This factor was applied to our observed
HR for all the candidate SNPs in Fig. 3, giving an empirical estimate from our data
of the OR for extreme long-livedness. Some studies did not report standard errors
for their ORs, merely p-value and effect estimate. We inferred standard errors,
assuming that a two-sided test with a normally distributed estimator had been used.
Genetic correlations. We estimated genetic correlations between mortality and
other traits using our both parents European ancestry GWAMA summary statistics
and the LDHub web portal (http://ldsc.broadinstitute.org/)49. As the parent
phenotype-offspring genotype GWAS halves the genetic effects4, both the genetic
covariance and sqrt(heritability) estimates are halved, resulting in 1:1 estimation of
the offspring-offspring genetic correlation(rg), from parental GWAS-offspring
GWAS based estimates of rg. LDHub estimates rg between one test GWAS and
~ 200 traits from metabolomics to common diseases such as cardiovascular disease
and lung cancer, using LD score regression9. Given their redundancy and number,
the metabolomic traits were excluded from the analysis. We added diastolic and
systolic blood pressure50, C-reactive protein (CRP)12 and breast cancer11 to the
traits present in LDhub49, using GWAMA summary statistics for these studies
provided to us. Each of these was run through the LDHub server in order to
estimate the genetic correlations with the other traits while the genetic correlation
with lifespan was estimated by using a local run of LD score regression. The
Benjamini and Hochberg multiple correction test procedure was applied to
determine the statistical signiﬁcance of the resulting genetic correlations.
We then deﬁned three categories of traits: (a) Meaningfully genetically
correlated to mortality if estimated rg> = 0.15 and FDR< 0.05; (b) Not
meaningfully genetically correlated to mortality if 95% CI for rg ⊂ [−0.15,0.15]; and
(c) Otherwise, insufﬁcient evidence.
After subsetting to only those meaningfully genetically correlated to mortality,
we estimated all genetic correlations among those traits; some pairs of traits
showed very high correlations. For example, many were genetically correlated to
BMI and obesity, we thus used the ICLUST clustering algorithm to cluster the most
similar ones. The number of clusters was chosen empirically, by visual inspection.
The ICLUST algorithm from the psych R package clusters items hierarchically
based on the loading of the items on the factors from factor analysis. Two clusters
are then merged together only if by their joining their internal consistency
increases. As rotation matrix for the factor analysis we used “promax” which is a
high efﬁciency algorithm which allows correlation between the different factors51.
Other than to deﬁne the initial list, mortality was not included in the clustering
analysis. At the same time, some highly correlated traits, which the clustering
algorithm sought to combine, appeared to capture distinct clinical aspects and
these were therefore kept separate. In particular, we split an education/smoking/
Table 3 Mendelian randomisation associations for the 19 traits with lifespan
Exposure SNPs in the IV Beta SE P-value Egger pleiotropy P SD Years per exposure unit Interquartile effect
in years
Risk factor
Body mass index SD
(kg/m2)
65 0.279 0.04 2.26 × 10−12 0.4 4.77 0.584 3.8
Years of schooling
SD (years)
64 −0.348 0.054 9.42 × 10−11 0.039 3.71 −0.937 −4.7
Cigarettes smoked
per day
rs12914385 0.034 0.005 6.47 × 10−10 − 11.7 0.338 5.3
HDL cholesterol SD
(mg/dL)
39 −0.106 0.044 0.017 0.793 15.5 −0.068 −1.4
LDL cholesterol SD
(mg/dL)
17 0.101 0.042 0.017 0.82 38.7 0.026 1.4
Fasting insulin log
pmol/L
6 0.389 0.176 0.027 0.823 0.79 3.89 4.1
SBP mmHg rs381815 0.02 0.009 0.031 − 18.9 0.204 5.2
CRP log mg/L 39 −0.046 0.021 0.033 0.073 1.08 −0.458 −0.66
DBP mmHg 3 0.029 0.015 0.056 0.248
Omega-3 fatty acids
(SD)
rs145717049 −0.229 0.182 0.208 −
Total cholesterol SD
(mg/dL)
11 0.036 0.068 0.597 0.348
Triglycerides SD
(mg/dL)
18 0.034 0.093 0.72 0.185
Apolipoprotein B
(SD)
3 0.013 0.067 0.846 0.918
Disease susceptibility
Alzheimer’s disease 18 0.035 0.013 0.009 0.783 − − 0.77
Breast cancer 109 0.034 0.007 7.11 × 10−6 0.318 − − 0.74
Coronary artery
disease
26 0.13 0.02 3.22 × 10−11 0.125 − − 2.9
Ischaemic stroke rs4984814 0.012 0.003 1.39 × 10−5 − − − 0.26
Squamous cell lung
cancer
2 0.073 0.03 0.014 − − − 1.6
Type 2 diabetes 22 0.036 0.015 0.02 0.247 − − 0.79
The 19 traits which were signiﬁcant in the ﬁrst step analysis are shown. Exposure, list of exposures tested (for traits in which the betas in the original GWAS were expressed in standard deviations, SD has
been added after the name of the exposure). Abbreviations/deﬁnitions: SNPs in the IV, the number of variants in the instrumental variable, or the identity of the SNP if< 2. Beta, effects of exposure on
lifespan expressed as the log hazard ratio of the Cox model, i.e., parent/offspring effect sizes have been doubled. For traits analysed in SD units, the betas refer to a variation of one standard deviation.
CRP, C-reactive protein, DBP, diastolic blood pressure, HDL, high-density lipoprotein, LDL, low-density lipoprotein, SE, the standard error of beta. Egger pleiotropy P refers to the p-value from the MR
Egger regression. SD, standard deviation of the exposure. Reduced years of life per exposure unit, reduction in lifespan expressed in years per measurement unit of the exposure (not SD units, even for
traits where beta is in SD units). A negative number indicates a longer lifespan. Interquartile effect on mortality (years), extrapolated difference in years of life between someone at the 3rd and 1st quartiles
of the phenotypic distribution, i.e., a 1.34 SD difference for quantitative traits and 2.2 points on the log(OR) scale for binary traits. SBP, systolic blood pressure
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rheumatoid arthritis group into three; we separated CAD out from the cluster
for dyslipidaemia and waist-hip ratio (DL/WHR) and we separated breast cancer
from age at menarche. The 12 clusters (and their constituent traits) were as follows:
obesity (body mass index, body fat, childhood obesity, extreme BMI, obesity class 1,
obesity class 2, obesity class 3, overweight, hip circumference, leptin_not adj,
leptin_adjbmi, waist circumference & CRP), smoking (cigarettes smoked per day,
former vs current smoker and lung cancer), DL/WHR (fasting insulin, extreme
waist-to-hip ratio, HDL cholesterol, insulin resistance (from homoeostasis
modelling assessment), triglycerides and waist-to-hip ratio), kidney (urinary
albumin-to-creatinine ratio and urinary albumin-to-creatinine ratio-non-
diabetics), type 2 diabetes (child birth weight, type 2 diabetes, fasting glucose and
haemoglobin A1c), blood pressure (systolic and diastolic), happiness (depressive
symptoms and subjective well-being), breast cancer, CAD, educational attainment
(years of schooling, openness to experience from NEO personality inventory),
rheumatoid arthritis and age at menarche.
The resulting correlation matrix amongst clusters was used to estimate partial
genetic correlations between the clusters using the matrix inversion method as
implemented in the corpcor R package (ISBN: 978-0-470-74366-9).
Mendelian randomisation. As a further step to identify which traits affect, rather
than merely correlate with, mortality and to determine how much they shorten
or lengthen lifespan, we performed a multiple step two-sample Mendelian
randomisation (MR) study using summary statistics. We ﬁrst identiﬁed a list of
96 candidate phenotypes selected amongst diseases and disease-associated risk
factors (Supplementary Table 2) for which genome-wide association data were
publicly available as part of the MRbase package. Data were available for more than
one GWAS for a given trait, we selected those which had the largest sample size,
were performed on both sexes and were performed in either European or Mixed
descent samples. To this list we added other GWAS which were not present in
MRbase: diastolic and systolic blood pressure, C-reactive protein and breast cancer.
For each of the selected traits, instrumental variables were constructed starting
from all SNPs with p < 5 × 10−8. We then performed LD clumping52 (r2= 0.1,
window= 10Mb) in order to prune all non-independent SNPS. Some traits had no
SNPs below the signiﬁcance threshold and were thus excluded.
MR was performed using the inverse variance method utilising each of the
selected traits as exposures and mortality as outcome. Where the instrument for the
trait was composed of a single SNP, we used the Wald ratio instead. We then
deﬁned as candidate traits all the phenotypes with a Benjamini and Hochberg FDR
< 0.05. We also veriﬁed the absence of directional pleiotropy using MR Egger
regression, but none of the candidate traits showed statistically signiﬁcant evidence
of pleiotropy once corrected for multiple testing (Supplementary Table 2).
Having already corrected for FDR at the previous step, no further adjustment was
made for multiple testing in Table 3.
Several traits associated with BMI and obesity were extremely redundant: we
thus removed obesity class 1, obesity class 2, obesity class 3, overweight, extreme
body mass index, hip circumference, and childhood obesity. Finally, myocardial
infarction was removed since 20 of the 22 SNPs composing its instrument were also
in the CAD instrument. Supplementary Table 3 summarises the number of SNPs
comprising each instrument before and after pruning.
For each signiﬁcant trait, we estimated the difference in expected years of life
between the 25th and 75th phenotypic percentiles. For normally distributed traits
this difference corresponds to 1.345 phenotypic standard deviations. For binary
traits, the variance of the logistic distribution is constant, this difference instead
corresponds to an interquartile distance of 2.2 times the beta coefﬁcient estimated
from the logistic regression. Thus, the difference in years between the two
considered quantiles was estimated to be:
75th 25th percentile distance ¼ 1:345 ´ SD ´ βHR ´ 10
For quantitative traits and
75th 25th percentile distance ¼ 2:2 ´ βHR ´ 10
This measure gives us the difference of expected lifespan between the two risk
quartiles expressed in years.
Data availability. All relevant data that support the ﬁndings of this study are
available from the corresponding author upon request or from UK Biobank,
LDHub, MRbase, BCAC, CHARGE-CRP53, 49, 10, 11, 12.
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